HOW TO ADVOCATE FOR YOUR CHILD WITH ACHONDROPLASIA IN A MEDICAL SETTING
the chandler project
Through advocacy, The Chandler Project brings awareness and shines a light on transformative research surrounding the most common form of skeletal dysplasia (dwarfism), achondroplasia, and other skeletal dysplasias by offering support to a global community and network of patients, parents, and caregivers seeking information on scientific discoveries, pharmaceutical advancements and surgical treatment options for those affected.
TCP is passionate about bringing you science from the source and believes that anyone seeking information on pharmaceutical research & developments and surgical advancements (limb lengthening) should have easy access to science directly from the source.
LATEST PHARMACEUTICAL NEWS FOR ACHONDROPLASIA
drug may reduce sudden infant death syndrome in children with achondroplasia
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomized, double-blind, placebo-controlled, phase 2 trial
Correspondence to: Professor Ravi Savarirayan, Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Parkville, VIC 3054, Australia ravi.savarirayan@vcgs.org.au
LATEST NEWS
treating achondroplasia & more
the following companies have or are developing pipelines for achondroplasia + other skeletal dysplasias & growth disorders
